Matthew Baker has been promoted to the position of chief executive officer at NeoPhore Ltd, an immuno-oncology company with technology for targeting DNA mismatch repair. He was previously the company’s vice president of immunology. Before joining NeoPhore, Dr Baker was the chief scientific officer at Denceptor Therapeutics Ltd, a joint venture between the Baylor Institute for Immunology Research and Abzena Plc. He has also led biologics discovery at Biovation Ltd.
Dr Baker obtained his PhD in cellular immunology at the University of Birmingham, UK.
NeoPhore announced the appointment on 17 March 2020.
Copyright 2020 Evernow Publishing Ltd.